JP2023519304A - 多発性骨髄腫における免疫療法の標的およびその同定方法 - Google Patents

多発性骨髄腫における免疫療法の標的およびその同定方法 Download PDF

Info

Publication number
JP2023519304A
JP2023519304A JP2022558042A JP2022558042A JP2023519304A JP 2023519304 A JP2023519304 A JP 2023519304A JP 2022558042 A JP2022558042 A JP 2022558042A JP 2022558042 A JP2022558042 A JP 2022558042A JP 2023519304 A JP2023519304 A JP 2023519304A
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022558042A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519304A5 (https=
Inventor
ペルナ，ファビアナ
Original Assignee
ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー filed Critical ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー
Publication of JP2023519304A publication Critical patent/JP2023519304A/ja
Publication of JP2023519304A5 publication Critical patent/JP2023519304A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2022558042A 2020-03-27 2021-03-26 多発性骨髄腫における免疫療法の標的およびその同定方法 Pending JP2023519304A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000694P 2020-03-27 2020-03-27
US63/000,694 2020-03-27
PCT/US2021/024431 WO2021195536A1 (en) 2020-03-27 2021-03-26 Immunotherapeutic targets in multiple myeloma and methods for their identification

Publications (2)

Publication Number Publication Date
JP2023519304A true JP2023519304A (ja) 2023-05-10
JP2023519304A5 JP2023519304A5 (https=) 2024-02-27

Family

ID=77890610

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022558042A Pending JP2023519304A (ja) 2020-03-27 2021-03-26 多発性骨髄腫における免疫療法の標的およびその同定方法

Country Status (8)

Country Link
US (1) US20230137672A1 (https=)
EP (1) EP4126243A4 (https=)
JP (1) JP2023519304A (https=)
KR (1) KR20220160053A (https=)
CN (1) CN116097096A (https=)
CA (1) CA3175860A1 (https=)
IL (1) IL296714A (https=)
WO (1) WO2021195536A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
WO2022031890A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr2 binding molecules and methods of use
US20230365696A1 (en) * 2020-08-05 2023-11-16 Synthekine, Inc. Ifngr1 binding molecules and methods of use
CN114031690B (zh) * 2021-12-03 2022-07-15 广州百暨基因科技有限公司 靶向ccr1和nkg2d配体的嵌合抗原受体及其应用
GB202117928D0 (en) 2021-12-11 2022-01-26 Cancer Research Tech Ltd Immunotherapy for cancer
CN116712550A (zh) * 2023-07-11 2023-09-08 中国医学科学院血液病医院(中国医学科学院血液学研究所) 治疗高增殖活性和多药耐药的多发性骨髓瘤的组合物及其应用
CN118501473A (zh) * 2024-05-22 2024-08-16 中国人民解放军海军军医大学第二附属医院 一种IgD型多发性骨髓瘤筛查试剂盒及其筛查系统
CN118878662A (zh) * 2024-09-03 2024-11-01 北京大学第六医院 多肽及其应用、试剂盒及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170074883A1 (en) * 2015-09-14 2017-03-16 Leukemia Therapeutics, LLC Identification of novel diagnostics and therapeutics by modulating rhoh
JP2018520653A (ja) * 2015-06-25 2018-08-02 イマティクス バイオテクノロジーズ ゲーエムベーハー 骨髄腫およびその他のがんの免疫療法において使用するための新規細胞エピトープおよび細胞エピトープ組み合わせ
JP2019530456A (ja) * 2016-09-28 2019-10-24 ガビッシュ−ガリラヤ バイオ アプリケーションズ リミテッド 癌の新規抗原性シグネチャーを標的としたｃａｒ療法のためのユニバーサルプラットフォーム

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046012A (en) * 1993-07-19 2000-04-04 Hoffmann-La Roche Inc. Antibody to IL-12 receptor
US20030092002A1 (en) * 1997-09-17 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2048901A (en) * 1999-11-29 2001-06-04 Trustees Of Columbia University In The City Of New York, The Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma
US8679771B2 (en) * 2007-01-25 2014-03-25 The Regents Of The University Of California Specific N-terminal labeling of peptides and proteins in complex mixtures
WO2012022634A1 (en) * 2010-08-16 2012-02-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Classification, diagnosis and prognosis of multiple myeloma
GB2495113A (en) * 2011-09-29 2013-04-03 Bioinvent Int Ab Anti-ICAM-1 antibody for treating multiple-myeloma-related disorders
WO2014082083A1 (en) * 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
WO2015121454A1 (en) * 2014-02-14 2015-08-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
SI3331910T1 (sl) * 2015-08-03 2020-07-31 Engmab Sarl Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA)
US20170234874A1 (en) * 2015-10-07 2017-08-17 Clearbridge Biophotonics Pte Ltd. Integrated visual morphology and cell protein expression using resonance-light scattering
FR3051555B1 (fr) * 2016-05-20 2018-05-11 Horiba Abx Sas Detection de la maladie residuelle du myelome multiple
WO2018027197A1 (en) * 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof
LT3535392T (lt) * 2016-11-02 2024-04-25 Universität Basel Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje
WO2019094360A1 (en) * 2017-11-07 2019-05-16 The Board Of Regents Of The University Of Texas System Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer
KR20250070609A (ko) * 2017-11-14 2025-05-20 아르셀엑스, 인크. 다기능성 면역 세포 요법
AU2018370217A1 (en) * 2017-11-17 2020-05-28 Memorial Sloan-Kettering Cancer Center Methods and compositions for alleviating Cytokine Release Syndrome
EA202091540A1 (ru) * 2017-12-22 2021-03-22 Джаунс Терапьютикс, Инк. Антитела к lilrb2
WO2020033585A1 (en) * 2018-08-07 2020-02-13 The Broad Institute, Inc. Methods for combinatorial screening and use of therapeutic targets thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018520653A (ja) * 2015-06-25 2018-08-02 イマティクス バイオテクノロジーズ ゲーエムベーハー 骨髄腫およびその他のがんの免疫療法において使用するための新規細胞エピトープおよび細胞エピトープ組み合わせ
US20170074883A1 (en) * 2015-09-14 2017-03-16 Leukemia Therapeutics, LLC Identification of novel diagnostics and therapeutics by modulating rhoh
JP2019530456A (ja) * 2016-09-28 2019-10-24 ガビッシュ−ガリラヤ バイオ アプリケーションズ リミテッド 癌の新規抗原性シグネチャーを標的としたｃａｒ療法のためのユニバーサルプラットフォーム

Also Published As

Publication number Publication date
KR20220160053A (ko) 2022-12-05
CA3175860A1 (en) 2021-09-30
IL296714A (en) 2022-11-01
CN116097096A (zh) 2023-05-09
WO2021195536A1 (en) 2021-09-30
US20230137672A1 (en) 2023-05-04
EP4126243A4 (en) 2024-06-12
EP4126243A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
JP2023519304A (ja) 多発性骨髄腫における免疫療法の標的およびその同定方法
CN114127091B (zh) 肿瘤新抗原多肽及其用途
AU2018244371B2 (en) Methods of isolating neoantigen-specific T cell receptor sequences
RU2138512C1 (ru) Вакцина для профилактики или лечения опосредованной т-клетками патологии или нерегулируемой репликации клонами т-клеток, способ выделения вакцины, способ диагностирования или прогнозирования восприимчивости к ревматоидному артриту или рассеянному склерозу, способ профилактики или лечения ревматоидного артрита или рассеянного склероза и содержащий последовательность sgdqggne пептид, являющийся агентом для обнаружения, профилактики или лечения рассеянного склероза
JP6556156B2 (ja) Ａｐｒｉｌバリアント
JP2023529026A (ja) Ｍｈｃ－ｉ発現を調節するための方法及びその免疫療法の使用
JP2022084710A (ja) Ｃａｒ－ｔ細胞の投薬を決定するための方法
CN112218888A (zh) 使用肿瘤微环境的特征的嵌合受体t细胞治疗
AU2018250336A1 (en) Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
US20150086575A1 (en) B cell surface reactive antibodies
JP7429338B2 (ja) 細胞療法および関連方法のエピジェネティック解析
WO2018132479A1 (en) Modified t cells and methods of their use
JP2022520230A (ja) 抗原特異的ｔ細胞の同定のための組成物と方法
WO2020018708A1 (en) Compositions and methods for treatment of t cell malignancies
JP7779484B2 (ja) 抗ｂ７－ｈ３モノクローナル抗体およびその使用方法
US20210322473A1 (en) Modified t cells and methods of their use
IL298279A (en) Immune cells with enhanced function
JP2019529437A (ja) 抗ｐｄ−ｌ１抗体単独療法に対する固形腫瘍の奏効性を特徴付けるための組成物および方法
CA3099928A1 (en) Chimeric antigen receptors targeting cd37 and cd19
TW202126696A (zh) 抗epha10抗體及其使用方法
JP7307424B2 (ja) 腫瘍浸潤ｔ細胞受容体レパトアの解析方法および該解析方法を用いたがん治療処置の有効性の判定方法
US20250276064A1 (en) Engineered chimeric fusion protein compositions and methods of use thereof
US20220105135A1 (en) Methods and compositions for the modulation of opioid signaling in the tumor microenvironment
WO2023177821A2 (en) Binding domains and methods of use thereof
WO2020010229A1 (en) Car t cell therapy to target t cell specific cancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260204